Tech Company Financing Transactions
AsclepiX Therapeutics Funding Round
AsclepiX Therapeutics, operating out of Baltimore, scored $5 million from Barer & Son Capital, Piedmont Angel Network and Rapha Capital Management.
Transaction Overview
Company Name
Announced On
11/14/2018
Transaction Type
Venture Equity
Amount
$5,000,000
Round
Undisclosed
Investors
Barer & Son Capital (Josh Barer)
Rapha Capital Management (Kevin Slawin)
Proceeds Purpose
With this investment, AsclepiX will accelerate development of AXT107, its innovative treatment for two leading causes of adult blindness: diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
301 West 29th St. 2004
Baltimore, MD 21211
USA
Baltimore, MD 21211
USA
Phone
Website
Email Address
Overview
AsclepiX Therapeutics is focussed on transforming the treatment of retinal disease and cancer through the rapid clinical development of groundbreaking therapies which may empower patients and families around the world with the freedom to live their best lives.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Kevin Slawin
Chief Medical Officer
Theresa Heah
Chief Scientific Officer
Aleksander Popel
Chief Technical Officer
Jordan Green
VP - R & D
Niranjan Pandey
VP - R & D
Huan Sheng
Browse more venture capital transactions:
Prev: 11/14/2018: NextCure venture capital transaction
Next: 11/14/2018: Netskope venture capital transaction
Share this article
Where The Data Comes From
We do our best to record all VC transactions involving tech companies. VC investment data records on this site are sourced from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs